WHC is still in active development. Read this to understand our approach.
depiction of CGNMLOKEMNBUAI-UHFFFAOYSA-N.svg
tripsit

adrafinil

Verificar en tripsit

psychonaut

Adrafinil

Verificar en psychonaut

isomerdesign

Adrafinil

Verificar en isomerdesign

druglab

Adrafinil

Verificar en druglab

wiki

Adrafinil

Verificar en wiki

Data

InChI: InChI=1S/C15H15NO3S/c17-14(16-18)11-20(19)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15,18H,11H2,(H,16,17)

Sinónimos: AKOS015994532,2-(BENZHYDRYLSULFINYL)-N-HYDROXYACETAMIDE,CRL40028,DTXCID2026498,HY-17549,AB07489,NCGC00165714-02,Acetamide, 2-((S)-(diphenylmethyl)sulfinyl)-N-hydroxy-,BI81Z4542G,547A137,Adrafinilum,UNII-BI81Z4542G,CRL-40028,AF-0056,2-[(Diphenylmethyl)sulfinyl]-N-hydroxyacetamide,DSSTox_RID_81667,BRN 1990030,Adrafinil (INN),D07348,DSSTox_CID_26498,2-benzhydrylsulfinyl-N-hydroxyacetamide,Adrafinil,2-((Diphenylmethyl)sulfinyl)-N-hydroxyacetamide,CCG-267371,63547-13-7,CRL 40028,Acetohydroxamic acid, 2-((diphenylmethyl)sulfinyl)-,2-((Diphenylmethyl)sulfinyl)acetohydroxamsaeure,F17382,s5224,827603-96-3,Adrafinil, (S)-,MFCD00865357,B1155,DSSTox_GSID_46498,Adrafinil, >=98% (HPLC), solid,SCHEMBL49334,2-[(diphenylmethyl)sulfinyl]-N-hydroxyacetamide,NCGC00165714-01,2-((Diphenylmethyl)sulfinyl)acetohydroxamic acid,ADRAFINIL [MI],DTXSID4046498,CAS-63547-13-7,ADRAFINIL [WHO-DD],HMS3886M15,CHEMBL93077,2-(Benzhydrylsulfinyl)acetohydroxamic acid,ADRAFINIL [MART.],Q366482,Tox21_112258,Olmifon (TN),2-(benzhydrylsulphinyl)acetohydroxamic acid,2-[(Diphenylmethyl)sulfinyl]acetohydroxamic acid,Adrafinil [INN],Acetamide, 2-[(S)-(diphenylmethyl)sulfinyl]-N-hydroxy-,W-104904,ADRAFINIL,ADRAFINIL [NFLIS-DRUG],EX-A733,CHEBI:135200,Acetamide, 2-((diphenylmethyl)sulfinyl)-N-hydroxy-,Adrafinilum [INN-Latin],Olmifon,EINECS 264-303-1

Estimated data

Solubilidad: -3.345 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 47.1% (prediction based on www.mdpi.com)

Similitudes

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.